Using the full-year 2025 filing and the previously reported first three quarters, Opus Genetics generated an estimated $3865000 of Q4 2025 collaboration revenue and an estimated net loss of $16523000. The quarter reflected higher R&D spending as the company advanced its gene therapy pipeline, while year-end cash and cash equivalents were $45091000.
Standalone Q4 2025 revenue was reconstructed at $3865000 from full-year and first-nine-month reported figures.
Estimated Q4 2025 net loss was $16523000, implying a wider loss than the first half of the year but lower than Q3 2025.
Estimated Q4 2025 research and development expense increased to $10428000.
Cash and cash equivalents at December 31, 2025 were $45091000.
Opus Genetics highlighted multiple 2026 catalysts across its inherited retinal disease pipeline and phentolamine program, while stating that post-quarter financing should extend cash runway into the first half of 2028.
Analyze how earnings announcements historically affect stock price performance